Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash.
Founded 20 years ago, Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.
Thermo Fisher executive vice-president Michel Lagarde said: “The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America.
“In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors.
“The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”
The viral vector manufacturing business offers over 7,000m² of advanced clinical and commercial manufacturing capacity.
With two locations in Seneffe and Gosselies, Henogen has around 400 employees with extensive operational and technical proficiency in various viral vector classes.
Novasep president and CEO Michel Spagnol said: “Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher.
“Our talented employees will bring deep expertise to an organisation that shares our commitment to providing ground-breaking new medicines to patients.”
The business will be part of the Pharma Services business within the Laboratory Products and Services Segment.
In March 2019, Thermo Fisher Scientific signed a definitive agreement to acquire viral vector manufacturing company Brammer Bio for a cash consideration of around $1.7bn.
Brammer Bio is focused on the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.